Ravulizumab for acute exacerbations in neuromyelitis optica spectrum disorder: A report of three cases

Key Points

• Ravulizumab effectively reduces acute exacerbations in neuromyelitis optica spectrum disorder, improving symptoms.
• In three cases, patients showed significant recovery following ravulizumab treatment, with improved clinical measures.
• Observational assessment of three cases illustrated clinical decisions on immunotherapy approaches for treatment options.
• Highlights the need for further studies to confirm findings in larger, diverse patient populations.